42 results on '"Andres López-Cortés"'
Search Results
2. Cardioembolic stroke in Chagas disease: unraveling the underexplored connection through a systematic review
- Author
-
Jorge Vásconez-González, Camila Miño, Juan S. Izquierdo-Condoy, Camila Salazar-Santoliva, Andrés López-Cortés, and Esteban Ortiz-Prado
- Subjects
Chagas Disease ,Trypanosoma Cruzi ,Stroke risk ,Cardioembolic Stroke ,Cerebrovascular complications ,Systematic review ,Arctic medicine. Tropical medicine ,RC955-962 - Abstract
Abstract Background Chagas disease (CD), triggered by the Trypanosoma cruzi parasite, is originally endemic across Latin America, affecting millions. While cardiac complications are widely recognized, the association between CD and stroke remains underexplored. This systematic review aims to elucidate the relationship between CD and stroke, highlighting the cardioembolic origins of stroke in CD patients and assessing the elevated stroke risk compared to non-infected individuals. Methodology Adhering to the PRISMA guidelines, we conducted a comprehensive search in PubMed and Scopus databases without date restrictions, including articles in both Spanish and English. This approach enabled the identification and analysis of relevant studies to understand the interplay between CD and stroke risk. Results Our analysis of 25 selected studies indicates that strokes in CD patients predominantly arise from cardioembolic sources. The data underscore a significant increase in stroke risk among individuals infected with T. cruzi compared to uninfected counterparts. Additionally, CD patients face a higher stroke and mortality risk than those with other heart failure etiologies, irrespective of disease severity. Conclusion The review establishes CD as a critical contributor to stroke incidence, emphasizing the need for heightened awareness and diagnosis of CD in stroke patients, particularly in regions with high CD prevalence. Recognizing the increased stroke risk associated with T. cruzi infection is crucial for developing targeted educational and preventive strategies in endemic areas.
- Published
- 2024
- Full Text
- View/download PDF
3. Unraveling druggable cancer-driving proteins and targeted drugs using artificial intelligence and multi-omics analyses
- Author
-
Andrés López-Cortés, Alejandro Cabrera-Andrade, Gabriela Echeverría-Garcés, Paulina Echeverría-Espinoza, Micaela Pineda-Albán, Nicole Elsitdie, José Bueno-Miño, Carlos M. Cruz-Segundo, Julian Dorado, Alejandro Pazos, Humberto Gonzáles-Díaz, Yunierkis Pérez-Castillo, Eduardo Tejera, and Cristian R. Munteanu
- Subjects
Medicine ,Science - Abstract
Abstract The druggable proteome refers to proteins that can bind to small molecules with appropriate chemical affinity, inducing a favorable clinical response. Predicting druggable proteins through screening and in silico modeling is imperative for drug design. To contribute to this field, we developed an accurate predictive classifier for druggable cancer-driving proteins using amino acid composition descriptors of protein sequences and 13 machine learning linear and non-linear classifiers. The optimal classifier was achieved with the support vector machine method, utilizing 200 tri-amino acid composition descriptors. The high performance of the model is evident from an area under the receiver operating characteristics (AUROC) of 0.975 ± 0.003 and an accuracy of 0.929 ± 0.006 (threefold cross-validation). The machine learning prediction model was enhanced with multi-omics approaches, including the target-disease evidence score, the shortest pathways to cancer hallmarks, structure-based ligandability assessment, unfavorable prognostic protein analysis, and the oncogenic variome. Additionally, we performed a drug repurposing analysis to identify drugs with the highest affinity capable of targeting the best predicted proteins. As a result, we identified 79 key druggable cancer-driving proteins with the highest ligandability, and 23 of them demonstrated unfavorable prognostic significance across 16 TCGA PanCancer types: CDKN2A, BCL10, ACVR1, CASP8, JAG1, TSC1, NBN, PREX2, PPP2R1A, DNM2, VAV1, ASXL1, TPR, HRAS, BUB1B, ATG7, MARK3, SETD2, CCNE1, MUTYH, CDKN2C, RB1, and SMARCA4. Moreover, we prioritized 11 clinically relevant drugs targeting these proteins. This strategy effectively predicts and prioritizes biomarkers, therapeutic targets, and drugs for in-depth studies in clinical trials. Scripts are available at https://github.com/muntisa/machine-learning-for-druggable-proteins .
- Published
- 2024
- Full Text
- View/download PDF
4. Worldwide analysis of actionable genomic alterations in lung cancer and targeted pharmacogenomic strategies
- Author
-
Gabriela Echeverría-Garcés, María José Ramos-Medina, Ariana González, Rodrigo Vargas, Alejandro Cabrera-Andrade, Isaac Armendáriz-Castillo, Jennyfer M. García-Cárdenas, David Ramírez-Sánchez, Adriana Altamirano-Colina, Paulina Echeverría-Espinoza, María Paula Freire, Belén Ocaña-Paredes, Sebastián Rivera-Orellana, Santiago Guerrero, Luis A. Quiñones, and Andrés López-Cortés
- Subjects
Science (General) ,Q1-390 ,Social sciences (General) ,H1-99 - Abstract
Based on data from the Global Cancer Statistics 2022, lung cancer stands as the most lethal cancer worldwide, with age-adjusted incidence and mortality rates of 23.6 and 16.9 per 100,000 people, respectively. Despite significant strides in precision oncology driven by large-scale international research consortia, there remains a critical need to deepen our understanding of the genomic landscape across diverse racial and ethnic groups. To address this challenge, we performed comprehensive in silico analyses and data mining to identify pathogenic variants in genes that drive lung cancer. We subsequently calculated the allele frequencies and assessed the deleteriousness of these oncogenic variants among populations such as African, Amish, Ashkenazi Jewish, East and South Asian, Finnish and non-Finnish European, Latino, and Middle Eastern. Our analysis examined 117,707 variants within 86 lung cancer-associated genes across 75,109 human genomes, uncovering 8042 variants that are known or predicted to be pathogenic. We prioritized variants based on their allele frequencies and deleterious scores, and identified those with potential significance for response to anti-cancer therapies through in silico drug simulations, current clinical pharmacogenomic guidelines, and ongoing late-stage clinical trials targeting lung cancer-driving proteins. In conclusion, it is crucial to unite global efforts to create public health policies that emphasize prevention strategies and ensure access to clinical trials, pharmacogenomic testing, and cancer research for these groups in developed nations.
- Published
- 2024
- Full Text
- View/download PDF
5. Direct health implications of e-cigarette use: a systematic scoping review with evidence assessment
- Author
-
Juan S. Izquierdo-Condoy, Patricio Naranjo-Lara, Estefanía Morales-Lapo, Marlon R. Hidalgo, Andrea Tello-De-la-Torre, Eduardo Vásconez-Gonzáles, Camila Salazar-Santoliva, Valentina Loaiza-Guevara, Wendy Rincón Hernández, Diego Alexander Becerra, María Belén Delgado González, Andrés López-Cortés, and Esteban Ortiz-Prado
- Subjects
E-cigarettes ,health effects ,tobacco harm reduction ,chronic effects of vaping ,systematic review ,Public aspects of medicine ,RA1-1270 - Abstract
BackgroundE-cigarettes are often marketed as a less harmful alternative to traditional tobacco cigarettes. Despite their popularity, the evidence regarding their effects on human health remains unclear and is filled with complexities.ObjectivesThis systematic review aims to elucidate the direct effects of electronic cigarette use on human health, carefully distinguishing between the specific characteristics of the populations studied.MethodologyAdhering to the PRISMA guidelines, we conducted a comprehensive search in PubMed/Medline, Web of Science, Scopus, and Google Scholar databases without date restrictions, including articles in both Spanish and English. This approach enabled the identification and analysis of primary studies to understand the direct effect of electronic cigarettes on human health.ResultsA total of 33 studies were included that evaluated cardiovascular, pulmonary, renal, weight and fertility effects. Only five studies analyzed e-cigarettes in healthy populations and seven studies compared healthy individuals against smokers. The effects evaluated on smokers or former tobacco smokers were apparently positive, however, among healthy individuals, increased heart rate, mean arterial pressure, oxidative stress, alteration of respiratory epithelial cells and increased airflow resistance were found.ConclusionSmokers or former smokers who switch to e-cigarettes may reduce their exposure to carcinogens and lower their risk of developing severe health issues associated with conventional smoking. However, in healthy individuals who have never smoked traditional cigarettes, the use of e-cigarettes introduces several cardiovascular and respiratory adverse effects. These findings suggest that while e-cigarettes can be a strategic harm reduction tool for smokers, they are not a safe option for non-smokers.
- Published
- 2024
- Full Text
- View/download PDF
6. Gastric cancer actionable genomic alterations across diverse populations worldwide and pharmacogenomics strategies based on precision oncology
- Author
-
Gabriela Echeverría-Garcés, María José Ramos-Medina, Rodrigo Vargas, Alejandro Cabrera-Andrade, Adriana Altamirano-Colina, María Paula Freire, Juliana Montalvo-Guerrero, Sebastián Rivera-Orellana, Paulina Echeverría-Espinoza, Luis A. Quiñones, and Andrés López-Cortés
- Subjects
gastric cancer ,precision oncology ,ethnic groups ,genomic alterations ,therapeutic strategies ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Introduction: Gastric cancer is one of the most prevalent types of cancer worldwide. The World Health Organization (WHO), the International Agency for Research on Cancer (IARC), and the Global Cancer Statistics (GLOBOCAN) reported an age standardized global incidence rate of 9.2 per 100,000 individuals for gastric cancer in 2022, with a mortality rate of 6.1. Despite considerable progress in precision oncology through the efforts of international consortia, understanding the genomic features and their influence on the effectiveness of anti-cancer treatments across diverse ethnic groups remains essential.Methods: Our study aimed to address this need by conducting integrated in silico analyses to identify actionable genomic alterations in gastric cancer driver genes, assess their impact using deleteriousness scores, and determine allele frequencies across nine global populations: European Finnish, European non-Finnish, Latino, East Asian, South Asian, African, Middle Eastern, Ashkenazi Jewish, and Amish. Furthermore, our goal was to prioritize targeted therapeutic strategies based on pharmacogenomics clinical guidelines, in silico drug prescriptions, and clinical trial data.Results: Our comprehensive analysis examined 275,634 variants within 60 gastric cancer driver genes from 730,947 exome sequences and 76,215 whole-genome sequences from unrelated individuals, identifying 13,542 annotated and predicted oncogenic variants. We prioritized the most prevalent and deleterious oncogenic variants for subsequent pharmacogenomics testing. Additionally, we discovered actionable genomic alterations in the ARID1A, ATM, BCOR, ERBB2, ERBB3, CDKN2A, KIT, PIK3CA, PTEN, NTRK3, TP53, and CDKN2A genes that could enhance the efficacy of anti-cancer therapies, as suggested by in silico drug prescription analyses, reviews of current pharmacogenomics clinical guidelines, and evaluations of phase III and IV clinical trials targeting gastric cancer driver proteins.Discussion: These findings underline the urgency of consolidating efforts to devise effective prevention measures, invest in genomic profiling for underrepresented populations, and ensure the inclusion of ethnic minorities in future clinical trials and cancer research in developed countries.
- Published
- 2024
- Full Text
- View/download PDF
7. The pharmacoepigenetic paradigm in cancer treatment
- Author
-
Belén Ocaña-Paredes, Sebastián Rivera-Orellana, David Ramírez-Sánchez, Juliana Montalvo-Guerrero, María Paula Freire, Samantha Espinoza-Ferrao, Adriana Altamirano-Colina, Paulina Echeverría-Espinoza, María José Ramos-Medina, Gabriela Echeverría-Garcés, Danilo Granda-Moncayo, Andrea Jácome-Alvarado, María Gabriela Andrade, and Andrés López-Cortés
- Subjects
epigenetic drugs ,histone deacetylase inhibitors ,histone acetyltransferase inhibitors ,histone methyltransferase inhibitors ,DNA methyltransferase inhibitors ,clinical trials ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Epigenetic modifications, characterized by changes in gene expression without altering the DNA sequence, play a crucial role in the development and progression of cancer by significantly influencing gene activity and cellular function. This insight has led to the development of a novel class of therapeutic agents, known as epigenetic drugs. These drugs, including histone deacetylase inhibitors, histone acetyltransferase inhibitors, histone methyltransferase inhibitors, and DNA methyltransferase inhibitors, aim to modulate gene expression to curb cancer growth by uniquely altering the epigenetic landscape of cancer cells. Ongoing research and clinical trials are rigorously evaluating the efficacy of these drugs, particularly their ability to improve therapeutic outcomes when used in combination with other treatments. Such combination therapies may more effectively target cancer and potentially overcome the challenge of drug resistance, a significant hurdle in cancer therapy. Additionally, the importance of nutrition, inflammation control, and circadian rhythm regulation in modulating drug responses has been increasingly recognized, highlighting their role as critical modifiers of the epigenetic landscape and thereby influencing the effectiveness of pharmacological interventions and patient outcomes. Epigenetic drugs represent a paradigm shift in cancer treatment, offering targeted therapies that promise a more precise approach to treating a wide spectrum of tumors, potentially with fewer side effects compared to traditional chemotherapy. This progress marks a step towards more personalized and precise interventions, leveraging the unique epigenetic profiles of individual tumors to optimize treatment strategies.
- Published
- 2024
- Full Text
- View/download PDF
8. CardiOmics signatures reveal therapeutically actionable targets and drugs for cardiovascular diseases
- Author
-
María José Ramos-Medina, Gabriela Echeverría-Garcés, Nikolaos C. Kyriakidis, Ángela León Cáceres, Esteban Ortiz-Prado, Jhommara Bautista, Álvaro A. Pérez-Meza, Andrea Abad-Sojos, Karol Nieto-Jaramillo, Samantha Espinoza-Ferrao, Belén Ocaña-Paredes, and Andrés López-Cortés
- Subjects
Science (General) ,Q1-390 ,Social sciences (General) ,H1-99 - Abstract
Cardiovascular diseases are the leading cause of death worldwide, with heart failure being a complex condition that affects millions of individuals. Single-nucleus RNA sequencing has recently emerged as a powerful tool for unraveling the molecular mechanisms behind cardiovascular diseases. This cutting-edge technology enables the identification of molecular signatures, intracellular networks, and spatial relationships among cardiac cells, including cardiomyocytes, mast cells, lymphocytes, macrophages, lymphatic endothelial cells, endocardial cells, endothelial cells, epicardial cells, adipocytes, fibroblasts, neuronal cells, pericytes, and vascular smooth muscle cells. Despite these advancements, the discovery of essential therapeutic targets and drugs for precision cardiology remains a challenge. To bridge this gap, we conducted comprehensive in silico analyses of single-nucleus RNA sequencing data, functional enrichment, protein interactome network, and identification of the shortest pathways to physiological phenotypes. This integrated multi-omics analysis generated CardiOmics signatures, which allowed us to pinpoint three therapeutically actionable targets (ADRA1A1, PPARG, and ROCK2) and 15 effective drugs, including adrenergic receptor agonists, adrenergic receptor antagonists, norepinephrine precursors, PPAR receptor agonists, and Rho-associated kinase inhibitors, involved in late-stage cardiovascular disease clinical trials.
- Published
- 2024
- Full Text
- View/download PDF
9. Genetic basis and spatial distribution of glucose-6-phosphate dehydrogenase deficiency in ecuadorian ethnic groups: a malaria perspective
- Author
-
Sebastián Atarihuana, Jennifer Gallardo-Condor, Andrés López-Cortés, Karina Jimenes-Vargas, Germán Burgos, Ana Karina-Zambrano, Rodrigo Flores-Espinoza, Marco Coral, and Alejandro Cabrera-Andrade
- Subjects
Glucose-6-phosphate dehydrogenase ,G6PD deficiency ,Single nucleotide variants ,Malaria clusters ,Ecuador ,Afro-Ecuadorians ,Arctic medicine. Tropical medicine ,RC955-962 ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background Glucose-6-phosphate dehydrogenase deficiency (G6PDd) is an X-linked disorder affecting over 400 million people worldwide. Individuals with molecular variants associated with reduced enzymatic activity are susceptible to oxidative stress in red blood cells, thereby increasing the risk of pathophysiological conditions and toxicity to anti-malarial treatments. Globally, the prevalence of G6PDd varies among populations. Accordingly, this study aims to characterize G6PDd distribution within the Ecuadorian population and to describe the spatial distribution of reported malaria cases. Methods Molecular variants associated with G6PDd were genotyped in 581 individuals from Afro-Ecuadorian, Indigenous, Mestizo, and Montubio ethnic groups. Additionally, spatial analysis was conducted to identify significant malaria clusters with high incidence rates across Ecuador, using data collected from 2010 to 2021. Results The A- c.202G > A and A- c.968T > C variants underpin the genetic basis of G6PDd in the studied population. The overall prevalence of G6PDd was 4.6% in the entire population. However, this frequency increased to 19.2% among Afro-Ecuadorian people. Spatial analysis revealed 12 malaria clusters, primarily located in the north of the country and its Amazon region, with relative risks of infection of 2.02 to 87.88. Conclusions The findings of this study hold significant implications for public health interventions, treatment strategies, and targeted efforts to mitigate the burden of malaria in Ecuador. The high prevalence of G6PDd among Afro-Ecuadorian groups in the northern endemic areas necessitates the development of comprehensive malaria eradication strategies tailored to this geographical region.
- Published
- 2023
- Full Text
- View/download PDF
10. Integrated multi-omics analysis reveals the molecular interplay between circadian clocks and cancer pathogenesis
- Author
-
Andy Pérez-Villa, Gabriela Echeverría-Garcés, María José Ramos-Medina, Lavanya Prathap, Mayra Martínez-López, David Ramírez-Sánchez, Jennyfer M. García-Cárdenas, Isaac Armendáriz-Castillo, Santiago Guerrero, Clara Paz, and Andrés López-Cortés
- Subjects
Medicine ,Science - Abstract
Abstract Circadian rhythms (CRs) are fundamental biological processes that significantly impact human well-being. Disruption of these rhythms can trigger insufficient neurocognitive development, insomnia, mental disorders, cardiovascular diseases, metabolic dysfunctions, and cancer. The field of chronobiology has increased our understanding of how rhythm disturbances contribute to cancer pathogenesis, and how circadian timing influences the efficacy of cancer treatments. As the circadian clock steadily gains recognition as an emerging factor in tumorigenesis, a thorough and comprehensive multi-omics analysis of CR genes/proteins has never been performed. To shed light on this, we performed, for the first time, an integrated data analysis encompassing genomic/transcriptomic alterations across 32 cancer types (n = 10,918 tumors) taken from the PanCancer Atlas, unfavorable prognostic protein analysis, protein–protein interactomics, and shortest distance score pathways to cancer hallmark phenotypes. This data mining strategy allowed us to unravel 31 essential CR-related proteins involved in the signaling crossroad between circadian rhythms and cancer. In the context of drugging the clock, we identified pharmacogenomic clinical annotations and drugs currently in late phase clinical trials that could be considered as potential cancer therapeutic strategies. These findings highlight the diverse roles of CR-related genes/proteins in the realm of cancer research and therapy.
- Published
- 2023
- Full Text
- View/download PDF
11. Data mining identifies novel RNA-binding proteins involved in colon and rectal carcinomas
- Author
-
Jennyfer M. García-Cárdenas, Isaac Armendáriz-Castillo, Nathali García-Cárdenas, David Pesantez-Coronel, Andrés López-Cortés, Alberto Indacochea, and Santiago Guerrero
- Subjects
RNA-binding proteins (RBPs) ,colorectal adenocarcinoma (COREAD) ,rectum ,colon ,biomarkers ,cancer ,Biology (General) ,QH301-705.5 - Abstract
Colorectal adenocarcinoma (COREAD) is the second most deadly cancer and third most frequently encountered malignancy worldwide. Despite efforts in molecular subtyping and subsequent personalized COREAD treatments, multidisciplinary evidence suggests separating COREAD into colon cancer (COAD) and rectal cancer (READ). This new perspective could improve diagnosis and treatment of both carcinomas. RNA-binding proteins (RBPs), as critical regulators of every hallmark of cancer, could fulfill the need to identify sensitive biomarkers for COAD and READ separately. To detect new RBPs involved in COAD and READ progression, here we used a multidata integration strategy to prioritize tumorigenic RBPs. We analyzed and integrated 1) RBPs genomic and transcriptomic alterations from 488 COAD and 155 READ patients, 2) ∼ 10,000 raw associations between RBPs and cancer genes, 3) ∼ 15,000 immunostainings, and 4) loss-of-function screens performed in 102 COREAD cell lines. Thus, we unraveled new putative roles of NOP56, RBM12, NAT10, FKBP1A, EMG1, and CSE1L in COAD and READ progression. Interestingly, FKBP1A and EMG1 have never been related with any of these carcinomas but presented tumorigenic features in other cancer types. Subsequent survival analyses highlighted the clinical relevance of FKBP1A, NOP56, and NAT10 mRNA expression to predict poor prognosis in COREAD and COAD patients. Further research should be performed to validate their clinical potential and to elucidate their molecular mechanisms underlying these malignancies.
- Published
- 2023
- Full Text
- View/download PDF
12. An 11-year epidemiological analysis of schistosomiasis in Ecuador: Investigating a non-endemic, neglected, and challenging-to-identify parasitic disease
- Author
-
Jorge Vásconez-González, Justin Yeager, Juan S. Izquierdo-Condoy, Raul Fernandez-Naranjo, María-Belén López, María Gabriela Dávila, Simone Cordovez, Andrés López-Cortés, and Esteban Ortiz-Prado
- Subjects
Schistosomiasis ,Zoonosis ,Epidemiology ,Neglected disease ,Ecuador ,Infectious and parasitic diseases ,RC109-216 - Abstract
Schistosomiasis is a neglected disease caused by parasites of the genus Schistosoma and transmitted by snails of the genus Biomphalaria. At least five species have the potential to infect humans living in or visiting tropical areas worldwide. In Latin America, Schistosoma mansoni is particularly common; however, it has not been reported in Ecuador. In this study, we assess the available official data on schistosomiasis in Ecuador to describe the prevalence of this neglected disease. We conducted a nationwide study to determine the demographic and spatial distribution patterns of schistosomiasis infection in Ecuador, using hospital discharge official data as a proxy for infection incidence from 2011 to 2021. We calculated crude and age-sex-adjusted morbidity and hospital admission rates by region, province, canton, and elevation. In the last decade of available data, schistosomiasis accounted for at least 551 hospital admissions in Ecuador. Women represented 53.7% (n = 296) of cases, equivalent to 3.2 cases per 1,000,000 inhabits. The highest number of cases (61.2%, n = 337) was found in the Coastal region. However, the highest incidence rates were observed in the Amazon region's provinces of Pastaza (173.44 cases/1,000,000).
- Published
- 2023
- Full Text
- View/download PDF
13. An updated examination of the perception of barriers for pharmacogenomics implementation and the usefulness of drug/gene pairs in Latin America and the Caribbean
- Author
-
Aimeé Salas-Hernández, Macarena Galleguillos, Matías Carrasco, Andrés López-Cortés, María Ana Redal, Dora Fonseca-Mendoza, Patricia Esperón, Farith González-Martínez, Ismael Lares-Asseff, Alberto Lazarowski, Verónica Loera-Castañeda, Diadelis Remírez, Matías F. Martínez, Rodrigo Vargas, Fabricio Rios-Santos, Antonio Macho, Juan P. Cayún, Germán R. Perez, Carolina Gutierrez, Leslie C. Cerpa, Tamara Leiva, Susan Calfunao, Lesly Xajil, Christopher Sandoval, Marcelo Suárez, Ariana Gonzalez, Gabriela Echeverría-Garcés, Luis Sullón-Dextre, Eugenia Cordero-García, Alexis R. Morales, Andrea Avendaño, Enrique Sánchez, Laura C. Bastone, Cesar Lara, Patricia Zuluaga-Arias, Ana María Soler, Julio Da Luz, Gabriela Burgueño-Rodríguez, Marcelo Vital, Elizabeth Reyes-Reyes, Alexander Huaccha, Yeimy V. Ariza, Naomi Tzul, Ana L. Rendón, Roberto Serrano, Larissa Acosta, Angelo Motta-Pardo, Leonardo Beltrán-Angarita, Erika Brand, Miguel A. Jiménez, Gladys Maribel Hidalgo-Lozada, Marina M. J. Romero-Prado, Karla Escobar-Castro, Mariel Umaña-Rivas, Juan D. Vivas, Paola Lagos, Yineth Ballén Martínez, Sharleth Quesada, Camila Calfio, Maria L. Arias, María A. Lavanderos, Dante D. Cáceres, Alberto Salazar-Granara, Nelson M. Varela, and Luis A. Quiñones
- Subjects
pharmacogenetics ,pharmacogenomics ,gene/drug pair ,barriers ,precision medicine ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Pharmacogenomics (PGx) is considered an emergent field in developing countries. Research on PGx in the Latin American and the Caribbean (LAC) region remains scarce, with limited information in some populations. Thus, extrapolations are complicated, especially in mixed populations. In this paper, we reviewed and analyzed pharmacogenomic knowledge among the LAC scientific and clinical community and examined barriers to clinical application. We performed a search for publications and clinical trials in the field worldwide and evaluated the contribution of LAC. Next, we conducted a regional structured survey that evaluated a list of 14 potential barriers to the clinical implementation of biomarkers based on their importance. In addition, a paired list of 54 genes/drugs was analyzed to determine an association between biomarkers and response to genomic medicine. This survey was compared to a previous survey performed in 2014 to assess progress in the region. The search results indicated that Latin American and Caribbean countries have contributed 3.44% of the total publications and 2.45% of the PGx-related clinical trials worldwide thus far. A total of 106 professionals from 17 countries answered the survey. Six major groups of barriers were identified. Despite the region’s continuous efforts in the last decade, the primary barrier to PGx implementation in LAC remains the same, the “need for guidelines, processes, and protocols for the clinical application of pharmacogenetics/pharmacogenomics”. Cost-effectiveness issues are considered critical factors in the region. Items related to the reluctance of clinicians are currently less relevant. Based on the survey results, the highest ranked (96%–99%) gene/drug pairs perceived as important were CYP2D6/tamoxifen, CYP3A5/tacrolimus, CYP2D6/opioids, DPYD/fluoropyrimidines, TMPT/thiopurines, CYP2D6/tricyclic antidepressants, CYP2C19/tricyclic antidepressants, NUDT15/thiopurines, CYP2B6/efavirenz, and CYP2C19/clopidogrel. In conclusion, although the global contribution of LAC countries remains low in the PGx field, a relevant improvement has been observed in the region. The perception of the usefulness of PGx tests in biomedical community has drastically changed, raising awareness among physicians, which suggests a promising future in the clinical applications of PGx in LAC.
- Published
- 2023
- Full Text
- View/download PDF
14. Editorial: Pharmacogenetics and pharmacogenomics in Latin America: ethnic variability, new insights in advances and perspectives: a RELIVAF-CYTED initiative, Volume II
- Author
-
Andrés López-Cortés, Patricia Esperón, Matías F. Martínez, María A. Redal, Alberto Lazarowski, Nelson M. Varela, Ismael Lares-Asseff, and Luis A. Quiñones
- Subjects
pharmacogenetics ,Latin America and the Caribbean ,clinical guidelines ,pharmacogenomics ,drugs ,Therapeutics. Pharmacology ,RM1-950 - Published
- 2023
- Full Text
- View/download PDF
15. The close interaction between hypoxia-related proteins and metastasis in pancarcinomas
- Author
-
Andrés López-Cortés, Lavanya Prathap, Esteban Ortiz-Prado, Nikolaos C. Kyriakidis, Ángela León Cáceres, Isaac Armendáriz-Castillo, Antonella Vera-Guapi, Verónica Yumiceba, Katherine Simbaña-Rivera, Gabriela Echeverría-Garcés, Jennyfer M. García-Cárdenas, Andy Pérez-Villa, Patricia Guevara-Ramírez, Andrea Abad-Sojos, Jhommara Bautista, Lourdes Puig San Andrés, Nelson Varela, and Santiago Guerrero
- Subjects
Medicine ,Science - Abstract
Abstract Many primary-tumor subregions exhibit low levels of molecular oxygen and restricted access to nutrients due to poor vascularization in the tissue, phenomenon known as hypoxia. Hypoxic tumors are able to regulate the expression of certain genes and signaling molecules in the microenvironment that shift it towards a more aggressive phenotype. The transcriptional landscape of the tumor favors malignant transformation of neighboring cells and their migration to distant sites. Herein, we focused on identifying key proteins that participate in the signaling crossroads between hypoxic environment and metastasis progression that remain poorly defined. To shed light on these mechanisms, we performed an integrated multi-omics analysis encompassing genomic/transcriptomic alterations of hypoxia-related genes and Buffa hypoxia scores across 17 pancarcinomas taken from the PanCancer Atlas project from The Cancer Genome Atlas consortium, protein–protein interactome network, shortest paths from hypoxia-related proteins to metastatic and angiogenic phenotypes, and drugs involved in current clinical trials to treat the metastatic disease. As results, we identified 30 hypoxia-related proteins highly involved in metastasis and angiogenesis. This set of proteins, validated with the MSK-MET Project, could represent key targets for developing therapies. The upregulation of mRNA was the most prevalent alteration in all cancer types. The highest frequencies of genomic/transcriptomic alterations and hypoxia score belonged to tumor stage 4 and positive metastatic status in all pancarcinomas. The most significantly associated signaling pathways were HIF-1, PI3K-Akt, thyroid hormone, ErbB, FoxO, mTOR, insulin, MAPK, Ras, AMPK, and VEGF. The interactome network revealed high-confidence interactions among hypoxic and metastatic proteins. The analysis of shortest paths revealed several ways to spread metastasis and angiogenesis from hypoxic proteins. Lastly, we identified 23 drugs enrolled in clinical trials focused on metastatic disease treatment. Six of them were involved in advanced-stage clinical trials: aflibercept, bevacizumab, cetuximab, erlotinib, ipatasertib, and panitumumab.
- Published
- 2022
- Full Text
- View/download PDF
16. Identification of key proteins in the signaling crossroads between wound healing and cancer hallmark phenotypes
- Author
-
Andrés López-Cortés, Estefanía Abarca, Leonardo Silva, Erick Velastegui, Ariana León-Sosa, Germania Karolys, Francisco Cabrera, and Andrés Caicedo
- Subjects
Medicine ,Science - Abstract
Abstract Wound healing (WH) and cancer seem to share common cellular and molecular processes that could work in a tight balance to maintain tissue homeostasis or, when unregulated, drive tumor progression. The “Cancer Hallmarks” comprise crucial biological properties that mediate the advancement of the disease and affect patient prognosis. These hallmarks have been proposed to overlap with essential features of the WH process. However, common hallmarks and proteins actively participating in both processes have yet to be described. In this work we identify 21 WH proteins strongly linked with solid tumors by integrated TCGA Pan-Cancer and multi-omics analyses. These proteins were associated with eight of the ten described cancer hallmarks, especially avoiding immune destruction. These results show that WH and cancer's common proteins are involved in the microenvironment modification of solid tissues and immune system regulation. This set of proteins, between WH and cancer, could represent key targets for developing therapies.
- Published
- 2021
- Full Text
- View/download PDF
17. Vaccine market and production capabilities in the Americas
- Author
-
Esteban Ortiz-Prado, Estefanía Espín, Jorge Vásconez, Nathalia Rodríguez-Burneo, Nikolaos C. Kyriakidis, and Andrés López-Cortés
- Subjects
Vaccines ,Latin America ,Market ,Vaccine coverages ,Economic dependence ,Arctic medicine. Tropical medicine ,RC955-962 - Abstract
Abstract In the Americas, The United States of America, Canada, Mexico, and Brazil are the top vaccine producers and the countries with the leading infrastructure for biological manufacturing. The North American countries have the most demanding legislation regulating and controlling these pharmaceuticals’ distribution and production. Some Latin American countries rank in the top 20 of worldwide vaccine manufacturers, with Cuba, Brazil, México and Colombia have a self-sufficient vaccine production of 72.7%, 54,2%; 25%; and 7.7%, respectively, of the national vaccine demand. On the other hand, the rest of Latin American countries cannot satisfy their demand for vaccines, and most of their efforts are associated with the distribution within their health systems rather than in transferring technology. Based on this literature review, the results suggest an increasing growth vaccine demand, not only for their growing populations and previously established demand but also for the recently exerted pressure due to the COVID-19 pandemic. Because the American continent has a marked inequality between the hegemonic producers of vaccines, the exporters, and those that depend heavily on importing these products, this could assert technological dependence in countries with rapid population growth and jeopardize the effectiveness of the two vaccination plans.
- Published
- 2021
- Full Text
- View/download PDF
18. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates
- Author
-
Nikolaos C. Kyriakidis, Andrés López-Cortés, Eduardo Vásconez González, Alejandra Barreto Grimaldos, and Esteban Ortiz Prado
- Subjects
Immunologic diseases. Allergy ,RC581-607 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract The new SARS-CoV-2 virus is an RNA virus that belongs to the Coronaviridae family and causes COVID-19 disease. The newly sequenced virus appears to originate in China and rapidly spread throughout the world, becoming a pandemic that, until January 5th, 2021, has caused more than 1,866,000 deaths. Hence, laboratories worldwide are developing an effective vaccine against this disease, which will be essential to reduce morbidity and mortality. Currently, there more than 64 vaccine candidates, most of them aiming to induce neutralizing antibodies against the spike protein (S). These antibodies will prevent uptake through the human ACE-2 receptor, thereby limiting viral entrance. Different vaccine platforms are being used for vaccine development, each one presenting several advantages and disadvantages. Thus far, thirteen vaccine candidates are being tested in Phase 3 clinical trials; therefore, it is closer to receiving approval or authorization for large-scale immunizations.
- Published
- 2021
- Full Text
- View/download PDF
19. Cytogenetic and genomic analysis of a patient with turner syndrome and t(2;12): a case report
- Author
-
Paola E. Leone, Verónica Yumiceba, Ariana Jijón-Vergara, Andy Pérez-Villa, Isaac Armendáriz-Castillo, Jennyfer M. García-Cárdenas, Santiago Guerrero, Patricia Guevara-Ramírez, Andrés López-Cortés, Ana K. Zambrano, Jesús M. Hernández-Rivas, Juan Luis García, and César Paz-y-Miño
- Subjects
Turner syndrome ,Reciprocal translocation ,Cytogenetics ,Genetic mapping arrays ,FISH ,Genetics ,QH426-470 - Abstract
Abstract Background Turner syndrome is a genetic disorder that affects women. It is caused by an absent or incomplete X chromosome, which can be presented in mosaicism or not. There are 12 cases of Turner syndrome patients who present structural alterations in autosomal chromosomes. Case presentation The present case report describes a patient with a reciprocal, maternally inherited translocation between chromosomes 2 and 12 with a mosaicism of X monosomy 45,X,t(2;12)(p13;q24)[95]/46,XX,t(2;12)(p13;q24)[5]. Through genetic mapping arrays, altered genes in the patient were determined within the 23 chromosome pairs. These genes were associated with the patient’s clinical features using a bioinformatics tool. Conclusion To our knowledge, this is the first case in which a translocation (2;12) is reported in a patient with Turner syndrome and confirmed by conventional cytogenetics, FISH and molecular genetics. Clinical features of our patient are closely related with the loss of one X chromosome, however mild intellectual disability can be likely explained by autosomal genes. The presence of familial translocations was a common finding, thus emphasizing the need for familiar testing for further genetic counselling.
- Published
- 2020
- Full Text
- View/download PDF
20. Perturbation-Theory Machine Learning (PTML) Multilabel Model of the ChEMBL Dataset of Preclinical Assays for Antisarcoma Compounds
- Author
-
Alejandro Cabrera-Andrade, Andrés López-Cortés, Cristian R. Munteanu, Alejandro Pazos, Yunierkis Pérez-Castillo, Eduardo Tejera, Sonia Arrasate, and Humbert González-Díaz
- Subjects
Chemistry ,QD1-999 - Published
- 2020
- Full Text
- View/download PDF
21. Pulmonary Inflammatory Response in Lethal COVID-19 Reveals Potential Therapeutic Targets and Drugs in Phases III/IV Clinical Trials
- Author
-
Andrés López-Cortés, Santiago Guerrero, Esteban Ortiz-Prado, Verónica Yumiceba, Antonella Vera-Guapi, Ángela León Cáceres, Katherine Simbaña-Rivera, Ana María Gómez-Jaramillo, Gabriela Echeverría-Garcés, Jennyfer M. García-Cárdenas, Patricia Guevara-Ramírez, Alejandro Cabrera-Andrade, Lourdes Puig San Andrés, Doménica Cevallos-Robalino, Jhommara Bautista, Isaac Armendáriz-Castillo, Andy Pérez-Villa, Andrea Abad-Sojos, María José Ramos-Medina, Ariana León-Sosa, Estefanía Abarca, Álvaro A. Pérez-Meza, Karol Nieto-Jaramillo, Andrea V. Jácome, Andrea Morillo, Fernanda Arias-Erazo, Luis Fuenmayor-González, Luis Abel Quiñones, and Nikolaos C. Kyriakidis
- Subjects
pulmonary inflammatory response ,clinical trials ,drugs ,lethal COVID-19 ,single nucleus RNA sequencing ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Background: It is imperative to identify drugs that allow treating symptoms of severe COVID-19. Respiratory failure is the main cause of death in severe COVID-19 patients, and the host inflammatory response at the lungs remains poorly understood.Methods: Therefore, we retrieved data from post-mortem lungs from COVID-19 patients and performed in-depth in silico analyses of single-nucleus RNA sequencing data, inflammatory protein interactome network, and shortest pathways to physiological phenotypes to reveal potential therapeutic targets and drugs in advanced-stage COVID-19 clinical trials.Results: Herein, we analyzed transcriptomics data of 719 inflammatory response genes across 19 cell types (116,313 nuclei) from lung autopsies. The functional enrichment analysis of the 233 significantly expressed genes showed that the most relevant biological annotations were inflammatory response, innate immune response, cytokine production, interferon production, macrophage activation, blood coagulation, NLRP3 inflammasome complex, and the TLR, JAK-STAT, NF-κB, TNF, oncostatin M signaling pathways. Subsequently, we identified 34 essential inflammatory proteins with both high-confidence protein interactions and shortest pathways to inflammation, cell death, glycolysis, and angiogenesis.Conclusion: We propose three small molecules (baricitinib, eritoran, and montelukast) that can be considered for treating severe COVID-19 symptoms after being thoroughly evaluated in COVID-19 clinical trials.
- Published
- 2022
- Full Text
- View/download PDF
22. Editorial: Pharmacogenetics and Pharmacogenomics in Latin America: Ethnic Variability, New Insights in Advances and Perspectives: A RELIVAF-CYTED Initiative
- Author
-
Patricia Esperón, Matías F. Martínez, María A. Redal, Alberto Lazarowski, Andrés López-Cortés, Nelson M. Varela, and Luis A. Quiñones
- Subjects
pharmacogenetics ,pharmacogenomics ,CYTED ,Latin America ,precision medicine ,Therapeutics. Pharmacology ,RM1-950 - Published
- 2022
- Full Text
- View/download PDF
23. Clinical, genomics and networking analyses of a high-altitude native American Ecuadorian patient with congenital insensitivity to pain with anhidrosis: a case report
- Author
-
Andrés López-Cortés, Ana Karina Zambrano, Patricia Guevara-Ramírez, Byron Albuja Echeverría, Santiago Guerrero, Eliana Cabascango, Andy Pérez-Villa, Isaac Armendáriz-Castillo, Jennyfer M. García-Cárdenas, Verónica Yumiceba, Gabriela Pérez-M, Paola E. Leone, and César Paz-y-Miño
- Subjects
CIPA ,Native American ,Ecuadorian ,NTRK1 ,Genomics analysis ,Internal medicine ,RC31-1245 ,Genetics ,QH426-470 - Abstract
Abstract Background Congenital insensitivity to pain with anhidrosis (CIPA) is an extremely rare autosomal recessive disorder characterized by insensitivity to pain, inability to sweat and intellectual disability. CIPA is caused by mutations in the neurotrophic tyrosine kinase receptor type 1 gene (NTRK1) that encodes the high-affinity receptor of nerve growth factor (NGF). Case presentation Here, we present clinical and molecular findings in a 9-year-old girl with CIPA. The high-altitude indigenous Ecuadorian patient presented several health problems such as anhidrosis, bone fractures, self-mutilation, osteochondroma, intellectual disability and Riga-Fede disease. After the mutational analysis of NTRK1, the patient showed a clearly autosomal recessive inheritance pattern with the pathogenic mutation rs763758904 (Arg602*) and the second missense mutation rs80356677 (Asp674Tyr). Additionally, the genomic analysis showed 69 pathogenic and/or likely pathogenic variants in 46 genes possibly related to phenotypic heterogeneity, including the rs324420 variant in the FAAH gene. The gene ontology enrichment analysis showed 28 mutated genes involved in several biological processes. As a novel contribution, the protein-protein interaction network analysis showed that NTRK1, SPTBN2 and GRM6 interact with several proteins of the pain matrix involved in the response to stimulus and nervous system development. Conclusions This is the first study that associates clinical, genomics and networking analyses in a Native American patient with consanguinity background in order to better understand CIPA pathogenesis.
- Published
- 2020
- Full Text
- View/download PDF
24. A deep analysis using panel-based next-generation sequencing in an Ecuadorian pediatric patient with anaplastic astrocytoma: a case report
- Author
-
Jennyfer M. García-Cárdenas, Ana Karina Zambrano, Patricia Guevara-Ramírez, Santiago Guerrero, Gabriel Runruil, Andrés López-Cortés, Jorge P. Torres-Yaguana, Isaac Armendáriz-Castillo, Andy Pérez-Villa, Verónica Yumiceba, Paola E. Leone, and César Paz-y-Miño
- Subjects
Pediatric anaplastic astrocytoma ,High-grade gliomas ,TP53 ,Li-Fraumeni syndrome ,Medicine - Abstract
Abstract Background Anaplastic astrocytoma is a rare disorder in children from 10 to 14 years of age, with an estimated 0.38 new cases per 100,000 people per year worldwide. Panel-based next-generation sequencing opens new possibilities for diagnosis and therapy of rare diseases such as this one. Because it has never been genetically studied in the Ecuadorian population, we chose to genetically characterize an Ecuadorian pediatric patient with anaplastic astrocytoma for the first time. Doing so allows us to provide new insights into anaplastic astrocytoma diagnosis and treatment. Case presentation Our patient was a 13-year-old Mestizo girl with an extensive family history of cancer who was diagnosed with anaplastic astrocytoma. According to ClinVar, SIFT, and PolyPhen, the patient harbored 354 genomic alterations in 100 genes. These variants were mostly implicated in deoxyribonucleic acid (DNA) repair. The top five most altered genes were FANCD2, NF1, FANCA, FANCI, and WRN. Even though TP53 presented only five mutations, the rs11540652 single-nucleotide polymorphism classified as pathogenic was found in the patient and her relatives; interestingly, several reports have related it to Li-Fraumeni syndrome. Furthermore, in silico analysis using the Open Targets Platform revealed two clinical trials for pediatric anaplastic astrocytoma (studying cabozantinib, ribociclib, and everolimus) and 118 drugs that target the patient’s variants, but the studies were not designed specifically to treat pediatric anaplastic astrocytoma. Conclusions Next-generation sequencing allows genomic characterization of rare diseases; for instance, this study unraveled a pathogenic single-nucleotide polymorphism related to Li-Fraumeni syndrome and identified possible new drugs that specifically target the patient’s variants. Molecular tools should be implemented in routine clinical practice for early detection and effective preemptive intervention delivery and treatment.
- Published
- 2020
- Full Text
- View/download PDF
25. A New Insight for the Identification of Oncogenic Variants in Breast and Prostate Cancers in Diverse Human Populations, With a Focus on Latinos
- Author
-
Nelson M. Varela, Patricia Guevara-Ramírez, Cristian Acevedo, Tomás Zambrano, Isaac Armendáriz-Castillo, Santiago Guerrero, Luis A. Quiñones, and Andrés López-Cortés
- Subjects
breast ,prostate ,oncogenic variants ,latino population ,precision oncology ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Background: Breast cancer (BRCA) and prostate cancer (PRCA) are the most commonly diagnosed cancer types in Latin American women and men, respectively. Although in recent years large-scale efforts from international consortia have focused on improving precision oncology, a better understanding of genomic features of BRCA and PRCA in developing regions and racial/ethnic minority populations is still required.Methods: To fill in this gap, we performed integrated in silico analyses to elucidate oncogenic variants from BRCA and PRCA driver genes; to calculate their deleteriousness scores and allele frequencies from seven human populations worldwide, including Latinos; and to propose the most effective therapeutic strategies based on precision oncology.Results: We analyzed 339,100 variants belonging to 99 BRCA and 82 PRCA driver genes and identified 18,512 and 15,648 known/predicted oncogenic variants, respectively. Regarding known oncogenic variants, we prioritized the most frequent and deleterious variants of BRCA (n = 230) and PRCA (n = 167) from Latino, African, Ashkenazi Jewish, East Asian, South Asian, European Finnish, and European non-Finnish populations, to incorporate them into pharmacogenomics testing. Lastly, we identified which oncogenic variants may shape the response to anti-cancer therapies, detailing the current status of pharmacogenomics guidelines and clinical trials involved in BRCA and PRCA cancer driver proteins.Conclusion: It is imperative to unify efforts where developing countries might invest in obtaining databases of genomic profiles of their populations, and developed countries might incorporate racial/ethnic minority populations in future clinical trials and cancer researches with the overall objective of fomenting pharmacogenomics in clinical practice and public health policies.
- Published
- 2021
- Full Text
- View/download PDF
26. Molecular Pathogenesis and New Therapeutic Dimensions for Spinal Muscular Atrophy
- Author
-
Andrés López-Cortés, Gabriela Echeverría-Garcés, and María José Ramos-Medina
- Subjects
spinal muscular atrophy ,SMN1 ,SMN2 ,recessive genetic disease ,Biology (General) ,QH301-705.5 - Abstract
The condition known as 5q spinal muscular atrophy (SMA) is a devastating autosomal recessive neuromuscular disease caused by a deficiency of the ubiquitous protein survival of motor neuron (SMN), which is encoded by the SMN1 and SMN2 genes. It is one of the most common pediatric recessive genetic diseases, and it represents the most common cause of hereditary infant mortality. After decades of intensive basic and clinical research efforts, and improvements in the standard of care, successful therapeutic milestones have been developed, delaying the progression of 5q SMA and increasing patient survival. At the same time, promising data from early-stage clinical trials have indicated that additional therapeutic options are likely to emerge in the near future. Here, we provide updated information on the molecular underpinnings of SMA; we also provide an overview of the rapidly evolving therapeutic landscape for SMA, including SMN-targeted therapies, SMN-independent therapies, and combinational therapies that are likely to be key for the development of treatments that are effective across a patient’s lifespan.
- Published
- 2022
- Full Text
- View/download PDF
27. Genetic Variations of the DPYD Gene and Its Relationship with Ancestry Proportions in Different Ecuadorian Trihybrid Populations
- Author
-
Camila Farinango, Jennifer Gallardo-Cóndor, Byron Freire-Paspuel, Rodrigo Flores-Espinoza, Gabriela Jaramillo-Koupermann, Andrés López-Cortés, Germán Burgos, Eduardo Tejera, and Alejandro Cabrera-Andrade
- Subjects
fluoropyrimidines ,DPYD ,single nucleotide variants ,pharmacogenetics ,ancestry analysis estimation ,Ecuadorian ethnic groups ,Medicine - Abstract
Dihydropyrimidine dehydrogenase is one of the main pharmacological metabolizers of fluoropyrimidines, a group of drugs widely used in clinical oncology. Around 20 to 30% of patients treated with fluoropyrimidines experience severe toxicity caused by a partial or total decrease in enzymatic activity. This decrease is due to molecular variants in the DPYD gene. Their prevalence and allelic frequencies vary considerably worldwide, so their description in heterogeneous groups such as the Ecuadorian population will allow for the description of pharmacogenetic variants and proper characterization of this population. Thus, we genotyped all the molecular variants with a predictive value for DPYD in a total of 410 Ecuadorian individuals belonging to Mestizo, Afro-Ecuadorian, and Indigenous ethnic groups. Moreover, we developed a genetic ancestry analysis using 46 autosomal ancestry informative markers. We determined 20 genetic variations in 5 amplified regions, including 3 novel single nucleotide variants. The allele frequencies for DPYD variants c.1627G>A (*5, rs1801159), c.1129-15T>C (rs56293913), c.1218G>A (rs61622928), rs1337752, rs141050810, rs2786783, rs2811178, and g.97450142G>A (chr1, GRCh38.p13) are significantly related to Native American and African ancestry proportions. In addition, the FST calculated from these variants demonstrates the closeness between Indigenous and Mestizo populations, and evidences genetic divergence between Afro-Ecuadorian groups when compared with Mestizo and Indigenous ethnic groups. In conclusion, the genetic variability in the DPYD gene is related to the genetic component of ancestral populations in different Ecuadorian ethnic groups. The absence and low frequency of variants with predictive value for fluoropyrimidine toxicity such as DPYD *2A, HapB3, and c.2846A>T (prevalent in populations with European ancestry) is consistent with the genetic background found.
- Published
- 2022
- Full Text
- View/download PDF
28. In silico Analyses of Immune System Protein Interactome Network, Single-Cell RNA Sequencing of Human Tissues, and Artificial Neural Networks Reveal Potential Therapeutic Targets for Drug Repurposing Against COVID-19
- Author
-
Andrés López-Cortés, Patricia Guevara-Ramírez, Nikolaos C. Kyriakidis, Carlos Barba-Ostria, Ángela León Cáceres, Santiago Guerrero, Esteban Ortiz-Prado, Cristian R. Munteanu, Eduardo Tejera, Doménica Cevallos-Robalino, Ana María Gómez-Jaramillo, Katherine Simbaña-Rivera, Adriana Granizo-Martínez, Gabriela Pérez-M, Silvana Moreno, Jennyfer M. García-Cárdenas, Ana Karina Zambrano, Yunierkis Pérez-Castillo, Alejandro Cabrera-Andrade, Lourdes Puig San Andrés, Carolina Proaño-Castro, Jhommara Bautista, Andreina Quevedo, Nelson Varela, Luis Abel Quiñones, and César Paz-y-Miño
- Subjects
COVID-19 ,immune system ,single-cell RNA sequencing ,artificial neural networks ,drug repurposing ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Background: There is pressing urgency to identify therapeutic targets and drugs that allow treating COVID-19 patients effectively.Methods: We performed in silico analyses of immune system protein interactome network, single-cell RNA sequencing of human tissues, and artificial neural networks to reveal potential therapeutic targets for drug repurposing against COVID-19.Results: We screened 1,584 high-confidence immune system proteins in ACE2 and TMPRSS2 co-expressing cells, finding 25 potential therapeutic targets significantly overexpressed in nasal goblet secretory cells, lung type II pneumocytes, and ileal absorptive enterocytes of patients with several immunopathologies. Then, we performed fully connected deep neural networks to find the best multitask classification model to predict the activity of 10,672 drugs, obtaining several approved drugs, compounds under investigation, and experimental compounds with the highest area under the receiver operating characteristics.Conclusion: After being effectively analyzed in clinical trials, these drugs can be considered for treatment of severe COVID-19 patients. Scripts can be downloaded at https://github.com/muntisa/immuno-drug-repurposing-COVID-19.
- Published
- 2021
- Full Text
- View/download PDF
29. Epidemiological, socio-demographic and clinical features of the early phase of the COVID-19 epidemic in Ecuador.
- Author
-
Esteban Ortiz-Prado, Katherine Simbaña-Rivera, Lenin Gómez Barreno, Ana Maria Diaz, Alejandra Barreto, Carla Moyano, Vannesa Arcos, Eduardo Vásconez-González, Clara Paz, Fernanda Simbaña-Guaycha, Martin Molestina-Luzuriaga, Raúl Fernández-Naranjo, Javier Feijoo, Aquiles R Henriquez-Trujillo, Lila Adana, Andrés López-Cortés, Isabel Fletcher, and Rachel Lowe
- Subjects
Arctic medicine. Tropical medicine ,RC955-962 ,Public aspects of medicine ,RA1-1270 - Abstract
The SARS-CoV-2 virus has spread rapidly around the globe. Nevertheless, there is limited information describing the characteristics and outcomes of COVID-19 patients in Latin America. We conducted a cross-sectional analysis of 9,468 confirmed COVID-19 cases reported in Ecuador. We calculated overall incidence, mortality, case fatality rates, disability adjusted life years, attack and crude mortality rates, as well as relative risk and relative odds of death, adjusted for age, sex and presence of comorbidities. A total of 9,468 positive COVID-19 cases and 474 deaths were included in the analysis. Men accounted for 55.4% (n = 5, 247) of cases and women for 44.6% (n = 4, 221). We found the presence of comorbidities, being male and older than 65 years were important determinants of mortality. Coastal regions were most affected by COVID-19, with higher mortality rates than the highlands. Fatigue was reported in 53.2% of the patients, followed by headache (43%), dry cough (41.7%), ageusia (37.1%) and anosmia (36.1%). We present an analysis of the burden of COVID-19 in Ecuador. Our findings show that men are at higher risk of dying from COVID-19 than women, and risk increases with age and the presence of comorbidities. We also found that blue-collar workers and the unemployed are at greater risk of dying. These early observations offer clinical insights for the medical community to help improve patient care and for public health officials to strengthen Ecuador's response to the outbreak.
- Published
- 2021
- Full Text
- View/download PDF
30. 15q Duplication Syndrome: Report on the First Patient from Ecuador with an Unusual Clinical Presentation
- Author
-
Esteban Ortiz-Prado, Ana Lucía Iturralde, Katherine Simbaña-Rivera, Lenin Gómez-Barreno, Iván Hidalgo, Mario Rubio-Neira, Nicolás Espinosa, Juan Izquierdo-Condoy, María Emilia Arteaga-Espinosa, Alex Lister, Andrés López-Cortés, and Alejandro Cabrera-Andrade
- Subjects
Medicine - Abstract
Background. The 15q11.1-13.1 duplication, also known as Dup15q syndrome, is a rare congenital disease affecting 1 in 30,000 to 1 in 60,000 children worldwide. This condition is characterized by the presence of at least one extra copy of genetical material within the Prader-Willi/Angelman Critical Region (PWACR) of the referred 15q11.2-q13.1 chromosome. Case Report. Our study presents the clinical and genetical features of the first patient with a denovo 15q11.2 interstitial duplication on the maternal allele (inv Dup15q) that mimics a milder Prader-Willi syndrome probably due to an atypical disruption of the SNHG14 gene. Methylation-specific MLPA analysis has confirmed the presence of a very unlikely duplication that lies between breakpoint 1 (BP1) and the middle of BP2 and BP3 (BP3). This atypical alteration might be linked to the milder patient’s clinical phenotype. Conclusions. This is the first Dup15q patient reported in Ecuador and of the very few in South America. This aberration has never been described in a patient with Dup15q, and the unusual clinical presentation is probably due to the atypical distal breakpoint occurring within the gene SNHG14 which lies between BP2 and BP3 and does not therefore contain the whole PWACR. If the duplication disrupted the gene, then it is possible that it is the cause of, or contributing to, the patient’s clinical phenotype.
- Published
- 2021
- Full Text
- View/download PDF
31. Oncology and Pharmacogenomics Insights in Polycystic Ovary Syndrome: An Integrative Analysis
- Author
-
Verónica Yumiceba, Andrés López-Cortés, Andy Pérez-Villa, Iván Yumiseba, Santiago Guerrero, Jennyfer M. García-Cárdenas, Isaac Armendáriz-Castillo, Patricia Guevara-Ramírez, Paola E. Leone, Ana Karina Zambrano, and César Paz-y-Miño
- Subjects
polycystic ovary syndrome (PCOS) ,endometrial cancer (EC) ,ovarian cancer (OC) ,breast cancer (BC) ,pharmacogenomics ,bioinformatic ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
Polycystic ovary syndrome (PCOS) is a heterogeneous endocrine disorder characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovaries. Epidemiological findings revealed that women with PCOS are prone to develop certain cancer types due to their shared metabolic and endocrine abnormalities. However, the mechanism that relates PCOS and oncogenesis has not been addressed. Herein, in this review article the genomic status, transcriptional and protein profiles of 264 strongly PCOS related genes (PRG) were evaluated in endometrial cancer (EC), ovarian cancer (OV) and breast cancer (BC) exploring oncogenic databases. The genomic alterations of PRG were significantly higher when compared with a set of non-diseases genes in all cancer types. PTEN had the highest number of mutations in EC, TP53, in OC, and FSHR, in BC. Based on clinical data, women older than 50 years and Black or African American females carried the highest ratio of genomic alterations among all cancer types. The most altered signaling pathways were p53 in EC and OC, while Fc epsilon RI in BC. After evaluating PRG in normal and cancer tissue, downregulation of the differentially expressed genes was a common feature. Less than 30 proteins were up and downregulated in all cancer contexts. We identified 36 highly altered genes, among them 10 were shared between the three cancer types analyzed, which are involved in the cell proliferation regulation, response to hormone and to endogenous stimulus. Despite limited PCOS pharmacogenomics studies, 10 SNPs are reported to be associated with drug response. All were missense mutations, except for rs8111699, an intronic variant characterized as a regulatory element and presumably binding site for transcription factors. In conclusion, in silico analysis revealed key genes that might participate in PCOS and oncogenesis, which could aid in early cancer diagnosis. Pharmacogenomics efforts have implicated SNPs in drug response, yet still remain to be found.
- Published
- 2020
- Full Text
- View/download PDF
32. Integrated In Silico Analyses Identify PUF60 and SF3A3 as New Spliceosome-Related Breast Cancer RNA-Binding Proteins
- Author
-
Jennyfer M. García-Cárdenas, Isaac Armendáriz-Castillo, Andy Pérez-Villa, Alberto Indacochea, Andrea Jácome-Alvarado, Andrés López-Cortés, and Santiago Guerrero
- Subjects
RBPs ,breast cancer ,cancer driver genes ,in silico analysis ,Biology (General) ,QH301-705.5 - Abstract
More women are diagnosed with breast cancer (BC) than any other type of cancer. Although large-scale efforts have completely redefined cancer, a cure remains unattainable. In that respect, new molecular functions of the cell should be investigated, such as post-transcriptional regulation. RNA-binding proteins (RBPs) are emerging as critical post-transcriptional modulators of tumorigenesis, but only a few have clear roles in BC. To recognize new putative breast cancer RNA-binding proteins, we performed integrated in silico analyses of all human RBPs (n = 1392) in three major cancer databases and identified five putative BC RBPs (PUF60, TFRC, KPNB1, NSF, and SF3A3), which showed robust oncogenic features related to their genomic alterations, immunohistochemical changes, high interconnectivity with cancer driver genes (CDGs), and tumor vulnerabilities. Interestingly, some of these RBPs have never been studied in BC, but their oncogenic functions have been described in other cancer types. Subsequent analyses revealed PUF60 and SF3A3 as central elements of a spliceosome-related cluster involving RBPs and CDGs. Further research should focus on the mechanisms by which these proteins could promote breast tumorigenesis, with the potential to reveal new therapeutic pathways along with novel drug-development strategies.
- Published
- 2022
- Full Text
- View/download PDF
33. Identification of Key Proteins from the Alternative Lengthening of Telomeres-Associated Promyelocytic Leukemia Nuclear Bodies Pathway
- Author
-
Isaac Armendáriz-Castillo, Katherine Hidalgo-Fernández, Andy Pérez-Villa, Jennyfer M. García-Cárdenas, Andrés López-Cortés, and Santiago Guerrero
- Subjects
ALT ,PML ,telomeres ,Pan-Cancer ,TCGA ,omics ,Biology (General) ,QH301-705.5 - Abstract
Alternative lengthening of telomeres-associated promyelocytic leukemia nuclear bodies (APBs) are a hallmark of telomere maintenance. In the last few years, APBs have been described as the main place where telomeric extension occurs in ALT-positive cancer cell lines. A different set of proteins have been associated with APBs function, however, the molecular mechanisms behind their assembly, colocalization, and clustering of telomeres, among others, remain unclear. To improve the understanding of APBs in the ALT pathway, we integrated multiomics analyses to evaluate genomic, transcriptomic and proteomic alterations, and functional interactions of 71 APBs-related genes/proteins in 32 Pan-Cancer Atlas studies from The Cancer Genome Atlas Consortium (TCGA). As a result, we identified 13 key proteins which showed distinctive mutations, interactions, and functional enrichment patterns across all the cancer types and proposed this set of proteins as candidates for future ex vivo and in vivo analyses that will validate these proteins to improve the understanding of the ALT pathway, fill the current research gap about APBs function and their role in ALT, and be considered as potential therapeutic targets for the diagnosis and treatment of ALT-positive cancers in the future.
- Published
- 2022
- Full Text
- View/download PDF
34. Multi‐institutional experience of genetic diagnosis in Ecuador: National registry of chromosome alterations and polymorphisms
- Author
-
César Paz‐y‐Miño, Verónica Yumiceba, Germania Moreta, Rosario Paredes, Mónica Ruiz, Ligia Ocampo, Arianne Llamos Paneque, Catalina Ochoa Pérez, Juan Carlos Ruiz‐Cabezas, Jenny Álvarez Vidal, Idarmis Jiménez Torres, Ramón Vargas‐Vera, Fernando Cruz, Víctor Hugo Guapi N, Martha Montalván, Sara Meneses Álvarez, Maribel Garzón Castro, Elizabeth Lamar Segura, María Augusta Recalde Báez, María Elena Naranjo, Nina Tambaco Jijón, María Sinche, Pedro Licuy, Ramiro Burgos, Fabián Porras‐Borja, Gabriela Echeverría‐Garcés, Andy Pérez‐Villa, Isaac Armendáriz‐Castillo, Jennyfer M. García‐Cárdenas, Santiago Guerrero, Patricia Guevara‐Ramírez, Andrés López‐Cortés, Ana Karina Zambrano, and Paola E. Leone
- Subjects
chromosome alterations ,chromosome polymorphisms ,cytogenetics ,genetic testing ,Genetics ,QH426-470 - Abstract
Abstract Background Detection of chromosomal abnormalities is crucial in various medical areas; to diagnose birth defects, genetic disorders, and infertility, among other complex phenotypes, in individuals across a wide range of ages. Hence, the present study wants to contribute to the knowledge of type and frequency of chromosomal alterations and polymorphisms in Ecuador. Methods Cytogenetic registers from different Ecuadorian provinces have been merged and analyzed to construct an open‐access national registry of chromosome alterations and polymorphisms. Results Of 28,806 karyotypes analyzed, 6,008 (20.9%) exhibited alterations. Down syndrome was the most frequent autosome alteration (88.28%), followed by Turner syndrome (60.50%), a gonosome aneuploidy. A recurrent high percentage of Down syndrome mosaicism (7.45%) reported here, as well as by previous Ecuadorian preliminary registries, could be associated with geographic location and admixed ancestral composition. Translocations (2.46%) and polymorphisms (7.84%) were not as numerous as autosomopathies (64.33%) and gonosomopathies (25.37%). Complementary to conventional cytogenetics tests, molecular tools have allowed identification of submicroscopic alterations regions or candidate genes which can be possibly implicated in patients' symptoms and phenotypes. Conclusion The Ecuadorian National Registry of Chromosome Alterations and Polymorphisms provides a baseline to better understand chromosomal abnormalities in Ecuador and therefore their clinical management and awareness. This data will guide public policy makers to promote and financially support cytogenetic and genetic testing.
- Published
- 2020
- Full Text
- View/download PDF
35. Tracking SARS-CoV-2: Novel Trends and Diagnostic Strategies
- Author
-
Linda P. Guaman-Bautista, Erick Moreta-Urbano, Claudia G. Oña-Arias, Marbel Torres-Arias, Nikolaos C. Kyriakidis, Koray Malcı, Nestor Jonguitud-Borrego, Leonardo Rios-Solis, Espiridion Ramos-Martinez, Andrés López-Cortés, and Carlos Barba-Ostria
- Subjects
COVID-19 ,nucleic acid amplification test ,antigen testing ,CRISPR-based diagnostics ,nanotechnology-based diagnostics ,automation ,Medicine (General) ,R5-920 - Abstract
The COVID-19 pandemic has had an enormous impact on economies and health systems globally, therefore a top priority is the development of increasingly better diagnostic and surveillance alternatives to slow down the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In order to establish massive testing and contact tracing policies, it is crucial to have a clear view of the diagnostic options available and their principal advantages and drawbacks. Although classical molecular methods such as RT-qPCR are broadly used, diagnostic alternatives based on technologies such as LAMP, antigen, serological testing, or the application of novel technologies such as CRISPR-Cas for diagnostics, are also discussed. The present review also discusses the most important automation strategies employed to increase testing capability. Several serological-based diagnostic kits are presented, as well as novel nanotechnology-based diagnostic methods. In summary, this review provides a clear diagnostic landscape of the most relevant tools to track COVID-19.
- Published
- 2021
- Full Text
- View/download PDF
36. Post-transcriptional Regulation of Colorectal Cancer: A Focus on RNA-Binding Proteins
- Author
-
Jennyfer M. García-Cárdenas, Santiago Guerrero, Andrés López-Cortés, Isaac Armendáriz-Castillo, Patricia Guevara-Ramírez, Andy Pérez-Villa, Verónica Yumiceba, Ana Karina Zambrano, Paola E. Leone, and César Paz-y-Miño
- Subjects
colorectal cancer ,RBPs ,post-transcriptional regulation ,oncogene ,tumor suppressor ,Biology (General) ,QH301-705.5 - Abstract
Colorectal cancer (CRC) is a major health problem with an estimated 1. 8 million new cases worldwide. To date, most CRC studies have focused on DNA-related aberrations, leaving post-transcriptional processes under-studied. However, post-transcriptional alterations have been shown to play a significant part in the maintenance of cancer features. RNA binding proteins (RBPs) are uprising as critical regulators of every cancer hallmark, yet little is known regarding the underlying mechanisms and key downstream oncogenic targets. Currently, more than a thousand RBPs have been discovered in humans and only a few have been implicated in the carcinogenic process and even much less in CRC. Identification of cancer-related RBPs is of great interest to better understand CRC biology and potentially unveil new targets for cancer therapy and prognostic biomarkers. In this work, we reviewed all RBPs which have a role in CRC, including their control by microRNAs, xenograft studies and their clinical implications.
- Published
- 2019
- Full Text
- View/download PDF
37. A quick guide for using Microsoft OneNote as an electronic laboratory notebook.
- Author
-
Santiago Guerrero, Andrés López-Cortés, Jennyfer M García-Cárdenas, Pablo Saa, Alberto Indacochea, Isaac Armendáriz-Castillo, Ana Karina Zambrano, Verónica Yumiceba, Andy Pérez-Villa, Patricia Guevara-Ramírez, Oswaldo Moscoso-Zea, Joel Paredes, Paola E Leone, and César Paz-Y-Miño
- Subjects
Biology (General) ,QH301-705.5 - Abstract
Scientific data recording and reporting systems are of a great interest for endorsing reproducibility and transparency practices among the scientific community. Current research generates large datasets that can no longer be documented using paper lab notebooks (PLNs). In this regard, electronic laboratory notebooks (ELNs) could be a promising solution to replace PLNs and promote scientific reproducibility and transparency. We previously analyzed five ELNs and performed two survey-based studies to implement an ELN in a biomedical research institute. Among the ELNs tested, we found that Microsoft OneNote presents numerous features related to ELN best functionalities. In addition, both surveyed groups preferred OneNote over a scientifically designed ELN (PerkinElmer Elements). However, OneNote remains a general note-taking application and has not been designed for scientific purposes. We therefore provide a quick guide to adapt OneNote to an ELN workflow that can also be adjusted to other nonscientific ELNs.
- Published
- 2019
- Full Text
- View/download PDF
38. A Multi-Objective Approach for Anti-Osteosarcoma Cancer Agents Discovery through Drug Repurposing
- Author
-
Alejandro Cabrera-Andrade, Andrés López-Cortés, Gabriela Jaramillo-Koupermann, Humberto González-Díaz, Alejandro Pazos, Cristian R. Munteanu, Yunierkis Pérez-Castillo, and Eduardo Tejera
- Subjects
osteosarcoma ,machine learning ,multi-objective model ,virtual screening ,drug repositioning ,Medicine ,Pharmacy and materia medica ,RS1-441 - Abstract
Osteosarcoma is the most common type of primary malignant bone tumor. Although nowadays 5-year survival rates can reach up to 60–70%, acute complications and late effects of osteosarcoma therapy are two of the limiting factors in treatments. We developed a multi-objective algorithm for the repurposing of new anti-osteosarcoma drugs, based on the modeling of molecules with described activity for HOS, MG63, SAOS2, and U2OS cell lines in the ChEMBL database. Several predictive models were obtained for each cell line and those with accuracy greater than 0.8 were integrated into a desirability function for the final multi-objective model. An exhaustive exploration of model combinations was carried out to obtain the best multi-objective model in virtual screening. For the top 1% of the screened list, the final model showed a BEDROC = 0.562, EF = 27.6, and AUC = 0.653. The repositioning was performed on 2218 molecules described in DrugBank. Within the top-ranked drugs, we found: temsirolimus, paclitaxel, sirolimus, everolimus, and cabazitaxel, which are antineoplastic drugs described in clinical trials for cancer in general. Interestingly, we found several broad-spectrum antibiotics and antiretroviral agents. This powerful model predicts several drugs that should be studied in depth to find new chemotherapy regimens and to propose new strategies for osteosarcoma treatment.
- Published
- 2020
- Full Text
- View/download PDF
39. TCGA Pan-Cancer Genomic Analysis of Alternative Lengthening of Telomeres (ALT) Related Genes
- Author
-
Isaac Armendáriz-Castillo, Andrés López-Cortés, Jennyfer García-Cárdenas, Patricia Guevara-Ramírez, Paola E. Leone, Andy Pérez-Villa, Verónica Yumiceba, Ana K. Zambrano, Santiago Guerrero, and César Paz-y-Miño
- Subjects
telomeres ,cancer ,ALT ,in silico ,Genetics ,QH426-470 - Abstract
Telomere maintenance mechanisms (TMM) are used by cancer cells to avoid apoptosis, 85–90% reactivate telomerase, while 10–15% use the alternative lengthening of telomeres (ALT). Due to anti-telomerase-based treatments, some tumors switch from a telomerase-dependent mechanism to ALT; in fact, the co-existence between both mechanisms has been observed in some cancers. Although different elements in the ALT pathway are uncovered, some molecular mechanisms are still poorly understood. Therefore, with the aim to identify potential molecular markers for the study of ALT, we combined in silico approaches in a 411 telomere maintenance gene set. As a consequence, we conducted a genomic analysis of these genes in 31 Pan-Cancer Atlas studies from The Cancer Genome Atlas and found 325,936 genomic alterations; from which, we identified 20 genes highly mutated in the cancer studies. Finally, we made a protein-protein interaction network and enrichment analysis to observe the main pathways of these genes and discuss their role in ALT-related processes, like homologous recombination and homology directed repair. Overall, due to the lack of understanding of the molecular mechanisms of ALT cancers, we proposed a group of genes, which after ex vivo validations, could represent new potential therapeutic markers in the study of ALT.
- Published
- 2020
- Full Text
- View/download PDF
40. Gene Prioritization through Consensus Strategy, Enrichment Methodologies Analysis, and Networking for Osteosarcoma Pathogenesis
- Author
-
Alejandro Cabrera-Andrade, Andrés López-Cortés, Gabriela Jaramillo-Koupermann, César Paz-y-Miño, Yunierkis Pérez-Castillo, Cristian R. Munteanu, Humbert González-Díaz, Alejandro Pazos, and Eduardo Tejera
- Subjects
gene prioritization ,osteosarcoma ,communality analysis ,pathogenesis ,early recognition ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Osteosarcoma is the most common subtype of primary bone cancer, affecting mostly adolescents. In recent years, several studies have focused on elucidating the molecular mechanisms of this sarcoma; however, its molecular etiology has still not been determined with precision. Therefore, we applied a consensus strategy with the use of several bioinformatics tools to prioritize genes involved in its pathogenesis. Subsequently, we assessed the physical interactions of the previously selected genes and applied a communality analysis to this protein−protein interaction network. The consensus strategy prioritized a total list of 553 genes. Our enrichment analysis validates several studies that describe the signaling pathways PI3K/AKT and MAPK/ERK as pathogenic. The gene ontology described TP53 as a principal signal transducer that chiefly mediates processes associated with cell cycle and DNA damage response It is interesting to note that the communality analysis clusters several members involved in metastasis events, such as MMP2 and MMP9, and genes associated with DNA repair complexes, like ATM, ATR, CHEK1, and RAD51. In this study, we have identified well-known pathogenic genes for osteosarcoma and prioritized genes that need to be further explored.
- Published
- 2020
- Full Text
- View/download PDF
41. Relationship of an hRAD54 gene polymorphism (2290 C/T) in an Ecuadorian population with chronic myelogenous leukemia
- Author
-
César Paz-y-Miño, Andrés López-Cortés, María José Muñoz, Bernardo Castro, Alejandro Cabrera, and María Eugenia Sánchez
- Subjects
cancer ,leukemia ,CML ,ALL ,hRAD54 ,2290 C/T polymorphism ,Genetics ,QH426-470 - Abstract
The hRAD54 gene is a key member of the RAD52 epistasis group involved in repair of double-strand breaks (DSB) by homologous recombination (HR). Thus, alterations of the normal function of these genes could generate genetic instability, shifting the normal process of the cell cycle, leading the cells to develop into cancer. In this work we analyzed exon 18 of the hRAD54 gene, which has been previously reported by our group to carry a silent polymorphism, 2290 C/T (Ala730Ala), associated to meningiomas. We performed a PCR-SSCP method to detect the polymorphism in 239 samples including leukemia and normal control population. The results revealed that the 2290 C/T polymorphism has frequencies of 0.1 for the leukemia and 0.1 for the control group. These frequencies show no statistical differences. Additionally, we dissected the leukemia group in chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL) to evaluate the polymorphism. The frequencies found in these subgroups were 0.14 for CML and 0.05 for ALL. We found statistically significant differences between CML patients and the control group (p < 0.05) but we did not find significant differences between ALL and the control group (p > 0.05). These results suggest a possible link between the 2290 C/T polymorphism of the hRAD54 gene and CML.
- Published
- 2010
42. State of Art of Cancer Pharmacogenomics in Latin American Populations
- Author
-
Andrés López-Cortés, Santiago Guerrero, María Ana Redal, Angel Tito Alvarado, and Luis Abel Quiñones
- Subjects
cancer ,single nucleotide polymorphism ,precision medicine ,Latin America ,pharmacogenetics ,pharmacogenomics ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Over the past decades, several studies have shown that tumor-related somatic and germline alterations predicts tumor prognosis, drug response and toxicity. Latin American populations present a vast geno-phenotypic diversity due to the great interethnic and interracial mixing. This genetic flow leads to the appearance of complex characteristics that allow individuals to adapt to endemic environments, such as high altitude or extreme tropical weather. These genetic changes, most of them subtle and unexplored, could establish a mutational profile to develop new pharmacogenomic therapies specific for Latin American populations. In this review, we present the current status of research on somatic and germline alterations in Latin America compared to those found in Caucasian and Asian populations.
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.